Libertas Bio, a Formation Bio subsidiary, License of Gusacitinib, a Dual JAK/SYK Inhibitor, to Sanofi
NEW YORK, June 23, 2025 /PRNewswire/ -- Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study.
Gusacitinib was acquired by Formation Bio (formerly known as TrialSpark) in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next stage of development, with Sanofi leveraging its global expertise in drug development and commercialization to explore its potential in new indications.
This transaction exemplifies Formation Bio's differentiated business model: identifying and acquiring high-potential clinical-stage assets. Formation Bio and Sanofi have several long-standing collaborations focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise. This latest transaction builds on that collaboration, further strengthening both companies' commitment to advancing promising therapies through innovative technology and scientific excellence.
Benjamine Liu, Co-Founder & CEO of Formation Bio, commented:
'Formation Bio is redefining drug development through radical efficiency at every step. We acquire high-potential assets, move quickly to unlock value, and partner at key inflection points. We're proud to have Sanofi as a world-class partner working together to accelerate innovation in medicine.'
About Formation Bio
Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients. For more information, please visit www.formation.bio.
Media Contact:
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html
SOURCE Formation Bio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
FromZero.ai Launches Favicon Gallery, Targeting Guinness World Record for Largest Digital Mosaic
Interactive online mosaic invites users worldwide to permanently claim custom favicon tiles as part of a record-setting digital artwork San Francisco, California, June 24, 2025 (GLOBE NEWSWIRE) -- today announced the launch of Favicon Gallery, a large-scale digital mosaic project inviting users to permanently claim custom favicon tiles on an interactive online canvas. The project is aiming to set a Guinness World Record for the largest digital mosaic of favicons built in the shortest time. Favicon Gallery by — Guinness World Record mosaic in Gallery features a 100,000-tile digital canvas where each tile can be claimed for $99.99 USD. Participants upload their own favicon image, link, and title, contributing to a growing visual record of internet culture. The project is designed to encourage creativity, community engagement, and bold participation in digital spaces. Created as a public 'from zero' experiment without initial funding or code, Favicon Gallery reflects a philosophy of action over hesitation, demonstrating how ideas can be built openly and collaboratively online. 'Favicon Gallery is a live demonstration of how taking action can drive creativity and progress in the digital world,' said creator Sylvester M. 'We hope this inspires others to contribute, take creative risks, and become part of an evolving piece of internet history.' As the mosaic fills, will formally apply to Guinness World Records for recognition as the world's largest digital favicon mosaic created in the shortest timeframe. The long-term vision is for Favicon Gallery to generate funding that will support future digital ventures and creative innovation through open, community-driven projects. Favicon Gallery transforms the small, often-overlooked favicon, the tiny icon seen in browser tabs, into a platform for digital expression. Each tile in the mosaic represents permanent online real estate, owned and curated by individual participants. The project showcases contributions from creators, entrepreneurs, brands, and communities around the world. Built publicly from day one, Favicon Gallery emphasizes transparency and accessibility. Its development is openly documented on social channels and the project site. Current milestones include reaching 10,000–20,000 claimed tiles as the team builds momentum toward the Guinness World Record Favicon GalleryFavicon Gallery is an interactive digital mosaic created by The platform invites users worldwide to claim custom favicon tiles, contributing to a global artwork that celebrates creativity, internet culture, and bold claim a tile or learn more, visit: Sylvester M. Creator, contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
S&P 500 Gains and Losses Today: Coinbase Shares Soar; Oil and Defense Stocks Drop
The S&P 500 added 1.1% on Tuesday, June 24, 2025, as optimism spread about a possible de-escalation in the conflict between Israel and Iran. Coinbase shares surged, extending their solid rally as Benchmark analysts boosted their price target on the cryptocurrency exchange operator's stock. The potential for an alleviation of geopolitical tensions contributed to a drop in oil prices, pressuring oil and gas stocks, while aerospace and defense stocks also lost U.S. equities indexes gained ground on Tuesday after President Donald Trump announced a ceasefire agreement between Iran and Israel, raising hopes for a more sustained drawdown in hostilities. Investors also kept an eye on Congressional testimony by Federal Reserve Chair Jerome Powell. Powell indicated that the central bank intends to maintain interest rates at their current levels until there is more clarity on tariff policy and its potential economic impact, despite the White House's calls for immediate rate cuts. The S&P 500 gained 1.1%, closing just beneath its record-high level set in February. The Dow was up 1.2%, while the Nasdaq jumped 1.4%. Shares of Coinbase Global (COIN), operator of the largest cryptocurrency exchange in the U.S., skyrocketed 12.1% on Tuesday to secure the S&P 500's top performance. Analysts at the research firm Benchmark lifted their price target on Coinbase stock, pointing to favorable legislative and regulatory developments and the company's initiatives to capitalize on them. Secretary of Health and Human Services Robert F. Kennedy Jr. announced that the department would launch a massive advertising campaign to encourage the use of wearable health devices. Kennedy specifically mentioned the benefits of glucose monitors for patients managing diabetes. Shares of glucose monitor manufacturer Dexcom (DXCM) surged 9.7%. Uber Technologies (UBER) shares jumped 7.5% as the ridesharing company debuted its robotaxi service in Atlanta. Uber's partnership with Waymo, the autonomous vehicle company owned by Google parent Alphabet (GOOGL), initially offers service in 65 square miles of Atlanta, around half the city's footprint. Carnival Corporation (CCL) posted better-than-expected sales and profits for its fiscal first quarter, and the cruise operator's shares sailed 6.9% higher. The company also boosted its full-year profit outlook, pointing to increases in passengers carried and passenger cruise days as well as declining costs. Shares of competitors Norwegian Cruise Line Holdings (NCLH) and Royal Caribbean Group (RCL) also advanced. AutoZone (AZO) shares dropped 3.6%, losing the most of any S&P 500 stock on Tuesday, following reports that a senior vice president at the auto parts retailer had sold a stake in the company worth more than $2.5 million. Investors often view large sales by company insiders as a negative signal for a stock. Crude oil futures tumbled as optimism around de-escalation in the Middle East helped alleviate potential supply concerns. Shares of energy company Occidental Petroleum (OXY) fell 3.3%, while Exxon Mobil shares (XOM) were down 3%. The potential for calming geopolitical tensions also pressured defense stocks. Northrop Grumman (NOC) shares dropped 3.2%, while shares of aerospace and defense peers RTX Corp. (RTX) and Lockheed Martin (LMT) also traded lower. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
FedEx shares drop in afterhours as soft guidance overshadows Q4 results beat
-- FedEx reported Tuesday current-quarter guidance that missed estimates offering fourth-quarter results that beat expectations as cost cuts boost performance. FedEx Corporation (NYSE:FDX) shares fell more than 4% following the report. FedEx reported earnings per share of $6.07 on revenue of $22.2 billion. Analysts polled by anticipated EPS of $5.96 on revenue of $21.84B. The beat was driven by structural cost reduction targets, with the company saying it achieved $2.2B of cost cuts in fiscal 2025. Looking to Q1, the company sees adjusted EPS of $3.40 to $4 on revenue growth of flat to 2%, missing estimates of $4.05 on revenue of $21.73B. The company also said it was targeting $1B of cost savings during articles FedEx shares drop in afterhours as soft guidance overshadows Q4 results beat AeroVironment shares fall despite earnings beat, strong guidance BlackBerry posts strong Q1 as QNX and Secure Comms lead growth, shares gain Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
